{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:58:41Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 17.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0957a-8dc7-7061-b6f9-1e9dec96a8f7\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: penfluridol\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 reg", "usd": 0.0, "recall": true }, "codex": { "seconds": 89.5, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0957a-8dba-76d2-8ebf-071cdf25c5f8\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: penfluridol\nRegistry id: vr.tr.penfluridol\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:53:40+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:28+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q2149707", "registryId": "vr.tr.penfluridol", "name": "penfluridol", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q2149707/", "model": { "registry_id": "vr.tr.penfluridol", "name": "penfluridol", "purpose": "Enable an agent to identify penfluridol, assess the identity and condition of a material sample, and determine which handling or use decisions its evidence supports.", "definition": "Penfluridol is a synthetic, long-acting diphenylbutylpiperidine antipsychotic whose dopamine D2 receptor antagonism supports its use in treating schizophrenia.", "scope_statement": "This model owns penfluridol as the chemical substance registered as vr.tr.penfluridol in PHY / PHY.MAT, including molecular identity, material quality, physical state, biological activity evidence, and substance-specific handling constraints.", "in_scope": [ "Molecular identity and cross-registry identifiers for penfluridol", "Chemical form, solid form, purity, impurities, and batch traceability", "Condition-dependent physical properties, solubility, and stability", "Evidence for pharmacological activity and persistence", "Substance hazards and jurisdiction-specific constraints on intended use" ], "out_of_scope": [ "Finished tablets, brands, packaging, and excipient formulations", "Patient diagnosis, prescribing, dose selection, and treatment monitoring", "Manufacturing routes and production equipment", "Separate molecular models for metabolites or related antipsychotics", "Clinical trials and disease models beyond their evidence links to penfluridol" ], "distinguishing_features": [ "The neutral parent must match C28H27ClF5NO and InChIKey MDLAAYDRRZXJIF-UHFFFAOYSA-N; the formula alone does not establish connectivity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Penfluridol)", "Its structure combines a piperidin-4-ol bearing a chlorotrifluoromethylphenyl group with an N-linked bis(4-fluorophenyl)butyl group, distinguishing it from related antipsychotics such as pimozide and haloperidol. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Penfluridol)", "CAS 26864-56-2, PubChem CID 33630, and EC 248-074-5 should resolve consistently to the parent substance. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Penfluridol)", "A tablet or branded medicine containing penfluridol is a related product, not an interchangeable representation of the isolated substance.", "Long-acting antipsychotic activity is a supporting role description, not an identity test or evidence that a particular sample is fit for medicinal use. [NCBI MeSH](https://www.ncbi.nlm.nih.gov/mesh/68010395)" ], "characteristics": [ { "name": "Parent molecular identity", "kind": "category", "unit_or_values": "C28H27ClF5NO; InChIKey MDLAAYDRRZXJIF-UHFFFAOYSA-N", "why_it_matters": "Anchors recognition to a defined molecular structure. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Penfluridol)" }, { "name": "Registry identifier concordance", "kind": "relation", "unit_or_values": "vr.tr.penfluridol; CAS 26864-56-2; PubChem CID 33630; EC 248-074-5", "why_it_matters": "Supports record matching while exposing mistaken product or chemical-form mappings. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Penfluridol)" }, { "name": "Chemical and solid form", "kind": "category", "unit_or_values": "Parent or explicitly identified alternative form; crystalline, amorphous, or unresolved; supporting analytical method", "why_it_matters": "Prevents properties of a salt, solvate, or different solid form from being silently assigned to the parent." }, { "name": "Assay and impurity profile", "kind": "measurement", "unit_or_values": "% w/w assay with reporting basis; individual impurities in % w/w or ppm; chromatographic area % separately identified", "why_it_matters": "Distinguishes actual penfluridol content from detector response and identifies limitations on sample use." }, { "name": "Solubility", "kind": "measurement", "unit_or_values": "mg/mL or mol/L with solvent, pH, temperature, chemical form, and equilibration method", "why_it_matters": "Determines whether preparation and assay concentrations are physically achievable." }, { "name": "Thermal behavior", "kind": "measurement", "unit_or_values": "Melting range or decomposition onset in °C with method; boiling behavior only if experimentally established", "why_it_matters": "Supports material characterization without confusing melting, decomposition, and boiling." }, { "name": "Stability and storage condition", "kind": "state", "unit_or_values": "Within specification, degraded, or unassessed; temperature, light, moisture, container, and elapsed time", "why_it_matters": "Connects sample history to whether identity, assay, and impurity evidence remain applicable." }, { "name": "Target activity", "kind": "measurement", "unit_or_values": "Ki, Kd, IC50, or EC50 in nM or µM with target, species, assay, and endpoint", "why_it_matters": "Separates binding and functional evidence and prevents unsupported transfer between experimental systems." }, { "name": "Pharmacokinetic persistence", "kind": "measurement", "unit_or_values": "Half-life in hours or days with species, route, formulation, regimen, sampling window, and estimation method", "why_it_matters": "Makes evidence for prolonged action interpretable without treating a single value as universal." }, { "name": "Hazard and use status", "kind": "relation", "unit_or_values": "Dated SDS and classification source; jurisdiction; research or medicinal context; applicable restrictions", "why_it_matters": "Distinguishes laboratory handling evidence from authorization of a medicinal product." } ], "affordances": [ "Match a candidate substance record to penfluridol using structure and concordant identifiers.", "Evaluate whether a batch's analytical evidence supports its claimed identity, content, and grade.", "Assess whether a proposed solvent and concentration are supported by measured solubility evidence.", "Flag storage excursions or degradation evidence that require sample reassessment.", "Compare penfluridol activity and persistence measurements within compatible experimental contexts.", "Route handling and use decisions to applicable safety evidence and jurisdiction-specific records." ], "agent_conduct": { "may": [ "Explain penfluridol as a long-acting oral antipsychotic and where it is authorized, from official sources.", "Report warnings and side effects from official labelling." ], "must_not": [ "Recommend, dose or adjust penfluridol for a specific person.", "Suggest giving antipsychotics to someone without their knowledge or consent.", "Advise stopping antipsychotic treatment without a clinician.", "Stigmatize people who take antipsychotics." ], "requires_human": [ "Starting, stopping or changing antipsychotic treatment for a patient." ] }, "ethics": { "considerations": [ "Antipsychotic treatment touches autonomy, consent and the risk of coercion.", "People with schizophrenia face stigma that careless language worsens." ], "affected_parties": [ "Patients with psychotic disorders", "Families and carers", "Prescribers" ] }, "owners": { "steward": "The prescriber and the pharmacist for each patient; medicines regulators authorize products.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identified by product label, active ingredient name and pack details rather than by appearance alone." ], "failure_modes_and_hazards": [ "Movement disorders.", "Heart rhythm effects.", "Sedation and impaired driving." ], "what_it_is_for": [ "Penfluridol is encountered in pharmaceutical research, chemical reference materials and medicinal products where it is authorized.", "Its long duration of action supports its use as an oral antipsychotic for schizophrenia under clinical supervision." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology assigns penfluridol code N05AG03 within diphenylbutylpiperidine antipsychotics." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q2149707: penfluridol", "url": "https://www.wikidata.org/wiki/Q2149707", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Penfluridol", "url": "https://en.wikipedia.org/wiki/Penfluridol", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "penfluridol-identity", "name": "Penfluridol identity", "description": "Resolve the registered name to the parent molecule and keep related chemical forms and products distinct.", "rationale": "Related antipsychotics, supplier labels, and medicine names cannot substitute for structural identification.", "layers": [ { "id": "molecular-recognition", "name": "Molecular recognition", "description": "Establish agreement between the proposed structure and penfluridol identifiers.", "findings": [ { "id": "parent-structure-match", "name": "Parent structure match", "description": "Record structural evidence sufficient to distinguish penfluridol from similarly named or pharmacologically related compounds.", "questions": [ { "text": "Does the candidate structure match the penfluridol reference connectivity and InChIKey?", "kind": "definition", "id": "parent-structure-match-q01" }, { "text": "Which inspected reference supports the mapping between that structure, CAS 26864-56-2, and CID 33630?", "kind": "provenance", "id": "parent-structure-match-q02" } ] } ] }, { "id": "substance-product-boundary", "name": "Substance and product boundary", "description": "Separate the parent substance from alternate forms, mixtures, and finished medicines.", "findings": [ { "id": "represented-material", "name": "Represented material", "description": "Identify precisely what a label or record represents before inheriting penfluridol properties.", "questions": [ { "text": "Does this record represent parent penfluridol, an explicitly characterized alternative chemical form, or a mixture containing it?", "kind": "boundary", "id": "represented-material-q01" }, { "text": "Which product or formulation model owns any brand, tablet strength, excipients, and release behavior?", "kind": "boundary", "id": "represented-material-q02" } ] } ] } ] }, { "id": "penfluridol-material-quality", "name": "Penfluridol material quality", "description": "Determine what a particular batch contains and what its analytical evidence establishes.", "rationale": "A correct substance name does not establish identity confirmation, purity, or suitability for an intended use.", "layers": [ { "id": "batch-authentication", "name": "Batch authentication", "description": "Connect a physical sample to provenance and identity testing.", "findings": [ { "id": "traceable-identity-evidence", "name": "Traceable identity evidence", "description": "Require sample-specific links between batch records, reference materials, and identity measurements.", "questions": [ { "text": "Which supplier, lot, certificate, and sampling record identify this penfluridol material?", "kind": "provenance", "id": "traceable-identity-evidence-q01" }, { "text": "Which orthogonal analytical results support identity rather than merely reproducing the supplier's label?", "kind": "measurement", "id": "traceable-identity-evidence-q02" } ] } ] }, { "id": "content-and-contaminants", "name": "Content and contaminants", "description": "Record penfluridol content and material components that affect interpretation or suitability.", "findings": [ { "id": "assay-basis-and-impurities", "name": "Assay basis and impurities", "description": "Keep quantitative content, chromatographic purity, residual solvents, water, and degradation products distinguishable.", "questions": [ { "text": "Is the reported penfluridol assay mass-based, dry-basis, or chromatographic area percentage, and how was it calibrated?", "kind": "measurement", "id": "assay-basis-and-impurities-q01" }, { "text": "Which identified and unidentified impurities were measured, with what detection limits and intended-use acceptance criteria?", "kind": "measurement", "id": "assay-basis-and-impurities-q02" } ] } ] } ] }, { "id": "penfluridol-physical-behavior", "name": "Penfluridol physical behavior", "description": "Describe form-dependent behavior during storage, characterization, and solution preparation.", "rationale": "Solid form and preparation conditions can change the material available to an assay without changing its nominal name.", "layers": [ { "id": "solid-state-and-stability", "name": "Solid state and stability", "description": "Connect solid-state observations and storage history to material condition.", "findings": [ { "id": "form-and-integrity", "name": "Form and integrity", "description": "Record measured phase, thermal transitions, and evidence of change without assuming an established polymorph catalogue.", "questions": [ { "text": "What solid form and melting or decomposition behavior were measured for this penfluridol sample, using which methods?", "kind": "measurement", "id": "form-and-integrity-q01" }, { "text": "Do storage history and repeat analysis support continued use, or require quarantine and reassessment?", "kind": "action", "id": "form-and-integrity-q02" } ] } ] }, { "id": "solution-preparation", "name": "Solution preparation", "description": "Establish the conditions under which the intended penfluridol concentration is available in solution.", "findings": [ { "id": "dissolved-concentration", "name": "Dissolved concentration", "description": "Distinguish nominal loading from measured dissolved material and track changes after dilution.", "questions": [ { "text": "What solubility is measured in the proposed solvent or assay medium at the relevant pH and temperature?", "kind": "measurement", "id": "dissolved-concentration-q01" }, { "text": "Does dilution or storage cause precipitation, adsorption loss, or degradation that changes the available penfluridol concentration?", "kind": "measurement", "id": "dissolved-concentration-q02" } ] } ] } ] }, { "id": "penfluridol-biological-evidence", "name": "Penfluridol biological evidence", "description": "Organize evidence for target activity and prolonged action while preserving experimental context.", "rationale": "Penfluridol's pharmacological role requires evidence beyond chemical identification, and experimental effects do not automatically establish clinical utility.", "layers": [ { "id": "target-and-effect-evidence", "name": "Target and effect evidence", "description": "Distinguish target binding, functional effects, and downstream observations.", "findings": [ { "id": "activity-interpretation", "name": "Activity interpretation", "description": "Attach each proposed mechanism or effect to the assay and exposure that support it.", "questions": [ { "text": "Which direct assays establish penfluridol activity at dopamine D2 or other proposed targets, and what endpoints do they measure?", "kind": "provenance", "id": "activity-interpretation-q01" }, { "text": "Are reported downstream effects distinguished from target engagement and nonspecific toxicity at the tested concentrations?", "kind": "boundary", "id": "activity-interpretation-q02" } ] } ] }, { "id": "persistence-and-exposure", "name": "Persistence and exposure", "description": "Capture the evidence underlying long duration of action.", "findings": [ { "id": "duration-evidence", "name": "Duration evidence", "description": "Separate measured elimination, tissue persistence, and pharmacodynamic duration rather than equating them.", "questions": [ { "text": "Which species, route, formulation, regimen, and sampling window support each reported penfluridol half-life?", "kind": "measurement", "id": "duration-evidence-q01" }, { "text": "What evidence separates effects of parent penfluridol, metabolites, tissue distribution, and formulation on observed duration?", "kind": "boundary", "id": "duration-evidence-q02" } ] } ] } ] }, { "id": "penfluridol-handling-and-use", "name": "Penfluridol handling and use", "description": "Connect material handling and intended use to applicable evidence and authority.", "rationale": "A pharmacologically active substance needs explicit handling evidence, while medicine authorization attaches to defined products and jurisdictions.", "layers": [ { "id": "laboratory-exposure-control", "name": "Laboratory exposure control", "description": "Establish applicable precautions for penfluridol powder, solutions, and waste.", "findings": [ { "id": "handling-evidence", "name": "Handling evidence", "description": "Use an applicable safety record and task-specific exposure assessment without inventing a universal hazard classification.", "questions": [ { "text": "Which dated SDS and jurisdiction support the hazard classification of this penfluridol material?", "kind": "provenance", "id": "handling-evidence-q01" }, { "text": "What containment, protective equipment, spill response, and waste route are supported for the quantity and physical form being handled?", "kind": "action", "id": "handling-evidence-q02" } ] } ] }, { "id": "permitted-use-context", "name": "Permitted use context", "description": "Separate material grade and research use from medicinal product authorization.", "findings": [ { "id": "use-eligibility", "name": "Use eligibility", "description": "Record the evidence needed before a specific material is accepted for its proposed use.", "questions": [ { "text": "What specification and documentation qualify this penfluridol batch for the proposed research or pharmaceutical purpose?", "kind": "action", "id": "use-eligibility-q01" }, { "text": "Which current jurisdiction-specific product record governs any medicinal-use claim, and where is that product modeled?", "kind": "boundary", "id": "use-eligibility-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This account is recalled knowledge; no sources were consulted.", "Confirm identifiers, current national authorization and product-specific indications against authoritative records.", "Purity specifications, solid forms, melting point, GHS classification and exposure limits are omitted because they are not recalled with sufficient confidence." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of penfluridol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "penfluridol", "note": "Names the active substance rather than a particular finished medicine." }, { "scheme": "CAS Registry Number", "value_or_pattern": "26864-56-2", "note": "Identifier for penfluridol." }, { "scheme": "WHO Anatomical Therapeutic Chemical (ATC) classification", "value_or_pattern": "N05AG03", "note": "Classified among diphenylbutylpiperidine antipsychotics." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of penfluridol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Oral treatment and maintenance management of schizophrenia.", "Once-weekly oral administration is a distinguishing feature of its long duration of action." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of penfluridol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass", "typical_range": "Approximately 523.97", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of penfluridol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Extrapyramidal adverse effects, including parkinsonism, akathisia and dystonia.", "Tardive dyskinesia associated with prolonged exposure.", "Hyperprolactinaemia and associated endocrine or reproductive effects.", "Rare but potentially life-threatening neuroleptic malignant syndrome.", "Long persistence in the body can prolong adverse effects after discontinuation." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of penfluridol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Marketing authorization, availability and approved prescribing information differ between countries." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of penfluridol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "pimozide", "difference": "A distinct diphenylbutylpiperidine antipsychotic with a different molecular structure and prescribing profile." }, { "name": "fluspirilene", "difference": "A related antipsychotic used in long-acting injectable form, whereas penfluridol is administered orally." }, { "name": "penfluridol tablet", "difference": "A finished medicinal product containing a specified amount of penfluridol plus excipients; penfluridol itself is the active chemical substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of penfluridol this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative specifications establish penfluridol assay methods, impurity limits, and reference-standard requirements for each intended grade?", "Which experimentally established solid forms, melting ranges, and decomposition behaviors belong to the parent substance rather than an alternative form or supplier-specific sample?", "What validated pH-dependent solubility and stability data support aqueous assay preparation and stock-solution storage?", "Which primary studies establish target selectivity, human pharmacokinetic variability, and the contributions of metabolites or tissue distribution to prolonged action?", "Which current jurisdiction-specific records establish applicable GHS classifications, any substance-specific occupational exposure limit, and authorized medicinal products?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 27 } }